Skip to main content
Top
Published in: Endocrine 2/2024

Open Access 09-01-2024 | Hyperprolactinemia | Original Article

Are prolactin levels efficient in predicting a pituitary lesion in patients with hyperprolactinemia?

Authors: Emanuele Varaldo, Daniela Cuboni, Nunzia Prencipe, Luigi Simone Aversa, Michela Sibilla, Fabio Bioletto, Alessandro Maria Berton, Valentina Gasco, Ezio Ghigo, Silvia Grottoli

Published in: Endocrine | Issue 2/2024

Login to get access

Abstract

Purpose

Data regarding the presence of a prolactin (PRL) threshold above which a pituitary magnetic resonance imaging (MRI) is mandatory in patients with hyperprolactinemia (hyperPRL) are controversial and derived primarily from studies focused on female populations. Aim of our study was to evaluate in a cohort of patients of both sexes with confirmed hyperPRL, the possible correlation between PRL values and the presence of pituitary abnormalities.

Methods

We retrospectively analyzed data from patients who underwent serial PRL sampling at our Division between January 2015 and December 2022. Patients diagnosed with monomeric hyperPRL at serial sampling and with subsequent contrast-enhanced MRI results available for the pituitary region were included in the study. Exclusion criteria were prior pituitary disease, severe renal insufficiency, liver cirrhosis, uncompensated primary hypothyroidism and ongoing therapy with hyperprolactinemic drugs. Physiological causes of hyperPRL were also ruled out.

Results

Out of the 1253 patients who underwent serial PRL sampling, 139 patients (101 women and 38 men) met the inclusion criteria: 106 (76.3%) patients had some form of pituitary disease, with microlesions observed in 69.8%, macrolesions in 25.5% and other findings in 4.7% of subjects. PRL values showed a modest accuracy in predicting the presence of a pituitary abnormality and the best cut-offs identified were >25 µg/L (AUC 0.767, p = 0.003) and >44.2 µg/L (AUC 0.697, p < 0.001) in men and women, respectively; however, if only patients with PRL values > 500 µg/L were excluded from the analysis, as they were already supposed to harbor a macroprolactinoma, PRL levels were not able to predict the presence of a macrolesion neither in men nor women.

Conclusion

Given the high prevalence of pituitary abnormalities in patients of both sexes with hyperPRL at serial sampling, performing a pituitary imaging in all cases of hyperPRL, even if mild, appears to be a cautious choice.
Literature
1.
go back to reference B.M. Biller, A. Luciano, P.G. Crosignani, M. Molitch, D. Olive et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J. Reprod. Med. 44, 1075–1084 (1999)PubMed B.M. Biller, A. Luciano, P.G. Crosignani, M. Molitch, D. Olive et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J. Reprod. Med. 44, 1075–1084 (1999)PubMed
4.
go back to reference M.E. Freeman, B. Kanyicska, A. Lerant, G. Nagy, Prolactin: structure, function, and regulation of secretion. Physiol. Rev. 80, 1523–1631 (2000)CrossRefPubMed M.E. Freeman, B. Kanyicska, A. Lerant, G. Nagy, Prolactin: structure, function, and regulation of secretion. Physiol. Rev. 80, 1523–1631 (2000)CrossRefPubMed
5.
go back to reference S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011)CrossRefPubMed S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori et al. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011)CrossRefPubMed
6.
go back to reference M.B. Whyte, S. Pramodh, L. Srikugan, J.A. Gilbert, J.P. Miell et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary 18, 319–325 (2015)CrossRefPubMed M.B. Whyte, S. Pramodh, L. Srikugan, J.A. Gilbert, J.P. Miell et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary 18, 319–325 (2015)CrossRefPubMed
7.
go back to reference A. Colao, Pituitary tumours: the prolactinoma. Best. Pr. Res Clin. Endocrinol. Metab. 23, 575–596 (2009)CrossRef A. Colao, Pituitary tumours: the prolactinoma. Best. Pr. Res Clin. Endocrinol. Metab. 23, 575–596 (2009)CrossRef
8.
go back to reference L. Vilar, M.C. Freitas, L.A. Naves, L.A. Casulari, M. Azevedo et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J. Endocrinol. Invest 31, 436–444 (2008)CrossRefPubMed L. Vilar, M.C. Freitas, L.A. Naves, L.A. Casulari, M. Azevedo et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J. Endocrinol. Invest 31, 436–444 (2008)CrossRefPubMed
9.
go back to reference N. Karavitaki, G. Thanabalasingham, H.C.A. Shore, R. Trifanescu, O. Ansorge et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin. Endocrinol. (Oxf.) 65, 524–529 (2006)CrossRefPubMed N. Karavitaki, G. Thanabalasingham, H.C.A. Shore, R. Trifanescu, O. Ansorge et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin. Endocrinol. (Oxf.) 65, 524–529 (2006)CrossRefPubMed
10.
go back to reference T. Rand, E. Kink, M. Sator, B. Schneider, J. Huber et al. MRI of microadenomas in patients with hyperprolactinaemia. Neuroradiology 38, 744–746 (1996)CrossRefPubMed T. Rand, E. Kink, M. Sator, B. Schneider, J. Huber et al. MRI of microadenomas in patients with hyperprolactinaemia. Neuroradiology 38, 744–746 (1996)CrossRefPubMed
11.
go back to reference F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf.) 65, 265–273 (2006)CrossRefPubMed F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf.) 65, 265–273 (2006)CrossRefPubMed
12.
go back to reference Petersenn S., Fleseriu M., Casanueva F.F., Giustina A., Biermasz N., et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat. Rev. Endocrinol. 1–19 (2023) Petersenn S., Fleseriu M., Casanueva F.F., Giustina A., Biermasz N., et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat. Rev. Endocrinol. 1–19 (2023)
13.
go back to reference A. Bayrak, P. Saadat, E. Mor, L. Chong, R.J. Paulson et al. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil. Steril. 84, 181–185 (2005)CrossRefPubMed A. Bayrak, P. Saadat, E. Mor, L. Chong, R.J. Paulson et al. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil. Steril. 84, 181–185 (2005)CrossRefPubMed
14.
go back to reference Z. Godinjak, E. Idrizbegovic, A. Rama, Correlation between hyperprolactinemia, MRI of hypophysis and clinical presentation in infertile patients. Med. Arch. 67, 22–24 (2013)CrossRefPubMed Z. Godinjak, E. Idrizbegovic, A. Rama, Correlation between hyperprolactinemia, MRI of hypophysis and clinical presentation in infertile patients. Med. Arch. 67, 22–24 (2013)CrossRefPubMed
15.
go back to reference I. Souter, L.M. Baltagi, T.L. Toth, J.C. Petrozza, Prevalence of hyperprolactinemia and abnormal magnetic resonance imaging findings in a population with infertility. Fertil. Steril. 94, 1159–1162 (2010)CrossRefPubMed I. Souter, L.M. Baltagi, T.L. Toth, J.C. Petrozza, Prevalence of hyperprolactinemia and abnormal magnetic resonance imaging findings in a population with infertility. Fertil. Steril. 94, 1159–1162 (2010)CrossRefPubMed
16.
go back to reference S.H. Hou, S. Grossman, M.E. Molitch, Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am. J. Kidney Dis. 6, 245–249 (1985)CrossRefPubMed S.H. Hou, S. Grossman, M.E. Molitch, Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am. J. Kidney Dis. 6, 245–249 (1985)CrossRefPubMed
17.
go back to reference H.J. Teede, M.L. Misso, M.F. Costello, A. Dokras, J. Laven et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum. Reprod. 33, 1602–1618 (2018)CrossRefPubMedPubMedCentral H.J. Teede, M.L. Misso, M.F. Costello, A. Dokras, J. Laven et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum. Reprod. 33, 1602–1618 (2018)CrossRefPubMedPubMedCentral
18.
go back to reference G. Beccuti, F. Guaraldi, G. Natta, V. Cambria, N. Prencipe et al. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. J. Endocrinol. Invest 44, 1699–1706 (2021)CrossRefPubMed G. Beccuti, F. Guaraldi, G. Natta, V. Cambria, N. Prencipe et al. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. J. Endocrinol. Invest 44, 1699–1706 (2021)CrossRefPubMed
19.
go back to reference P. Chanson, D. Maiter, The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best. Pr. Res Clin. Endocrinol. Metab. 33, 101290 (2019)CrossRef P. Chanson, D. Maiter, The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best. Pr. Res Clin. Endocrinol. Metab. 33, 101290 (2019)CrossRef
20.
go back to reference I. Shimon, Y. Rudman, Y. Manisterski, A. Gorshtein, H. Masri et al. True hyperprolactinemia in men without visible pituitary adenoma. Endocrine 72, 809–813 (2021)CrossRefPubMed I. Shimon, Y. Rudman, Y. Manisterski, A. Gorshtein, H. Masri et al. True hyperprolactinemia in men without visible pituitary adenoma. Endocrine 72, 809–813 (2021)CrossRefPubMed
21.
go back to reference C. Di Somma, E. Scarano, G. de Alteriis, L. Barrea, E. Riccio et al. Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature. J. Endocrinol. Invest 44, 957–968 (2021)CrossRefPubMed C. Di Somma, E. Scarano, G. de Alteriis, L. Barrea, E. Riccio et al. Is there any gender difference in epidemiology, clinical presentation and co-morbidities of non-functioning pituitary adenomas? A prospective survey of a National Referral Center and review of the literature. J. Endocrinol. Invest 44, 957–968 (2021)CrossRefPubMed
22.
go back to reference C. Delcour, G. Robin, J. Young, D. Dewailly, PCOS and Hyperprolactinemia: what do we know in 2019? Clin. Med Insights Reprod. Health 13, 1179558119871921 (2019)CrossRefPubMedPubMedCentral C. Delcour, G. Robin, J. Young, D. Dewailly, PCOS and Hyperprolactinemia: what do we know in 2019? Clin. Med Insights Reprod. Health 13, 1179558119871921 (2019)CrossRefPubMedPubMedCentral
Metadata
Title
Are prolactin levels efficient in predicting a pituitary lesion in patients with hyperprolactinemia?
Authors
Emanuele Varaldo
Daniela Cuboni
Nunzia Prencipe
Luigi Simone Aversa
Michela Sibilla
Fabio Bioletto
Alessandro Maria Berton
Valentina Gasco
Ezio Ghigo
Silvia Grottoli
Publication date
09-01-2024
Publisher
Springer US
Published in
Endocrine / Issue 2/2024
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03678-z

Other articles of this Issue 2/2024

Endocrine 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine